Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: Fasudil exacerbates muscle disease phenotype

PLoS ONE

Volumn 5, Issue 9, 2010, Pages

  Rayavarapu, Sree ^a,b   Van der meulen, Jack H ^a   Gordish Dressman, Heather ^a   Hoffman, Eric P ^a,c   Nagaraju, Kanneboyina ^a,c   Knoblach, Susan M ^a,c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DYSFERLIN; FASUDIL; RHO KINASE; RHO KINASE INHIBITOR; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; DRUG DERIVATIVE; DYSF PROTEIN, MOUSE; MEMBRANE PROTEIN; PROTEIN KINASE INHIBITOR;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL INFILTRATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; EFFECT SIZE; ENZYME ACTIVATION; FUNCTIONAL STATUS; GRIP STRENGTH; INFLAMMATION; MACROPHAGE; MALE; MONOCYTE; MOUSE; MUSCLE ATROPHY; MUSCLE DISEASE; MUSCLE FORCE; MUSCLE REGENERATION; MUSCLE TISSUE; MYOPATHY; NONHUMAN; OPEN FIELD BEHAVIOR; PHENOTYPE; PROTEIN DEFICIENCY; SIGNAL TRANSDUCTION; SOLEUS MUSCLE; SWISS JAMES LAMBERT MOUSE; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; METABOLISM; MOUSE MUTANT; MUSCLE CONTRACTION; PATHOPHYSIOLOGY;

MUS;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE CONTRACTION; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; PROTEIN KINASE INHIBITORS;

EID: 77958615679     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012981     Document Type: Article

References (48)

1. Liu J, Aoki M, Illa I, Wu C, Fardeau M, et al. (1998) Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20: 31-36.
2. Glover L, Brown RH, Jr. (2007) Dysferlin in membrane trafficking and patch repair. Traffic 8: 785-794.
3. De Luna N, Freixas A, Gallano P, Caselles L, Rojas-Garcia R, et al. (2007) Dysferlin expression in monocytes: a source of mRNA for mutation analysis. Neuromuscul Disord 17: 69-76.
4. Nagaraju K, Rawat R, Veszelovszky E, Thapliyal R, Kesari A, et al. (2008) Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol 172: 774-785.
5. Gallardo E, Rojas-Garcia R, de Luna N, Pou A, Brown RH, Jr., et al. (2001) Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 57: 2136-2138.
6. Confalonieri P, Oliva L, Andreetta F, Lorenzoni R, Dassi P, et al. (2003) Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 142: 130-136.
7. Vafiadaki E, Reis A, Keers S, Harrison R, Anderson LV, et al. (2001) Cloning of the mouse dysferlin gene and genomic characterization of the SJL-Dysf mutation. Neuroreport 12: 625-629.
8. Bittner RE, Anderson LV, Burkhardt E, Bashir R, Vafiadaki E, et al. (1999) Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet 23: 141-142.
9. Nemoto H, Konno S, Nakazora H, Miura H, Kurihara T (2007) Histological and immunohistological changes of the skeletal muscles in older SJL/J mice. Eur Neurol 57: 19-25.
10. Weller AH, Magliato SA, Bell KP, Rosenberg NL (1997) Spontaneous myopathy in the SJL/J mouse: pathology and strength loss. Muscle Nerve 20: 72-82.
11. Suzuki K (2005) [Osteopontin-gene, structure and biosynthesis]. Nippon Rinsho 63 Suppl 10: 608-612.
12. Yeh BJ, Rutigliano RJ, Deb A, Bar-Sagi D, Lim WA (2007) Rewiring cellular morphology pathways with synthetic guanine nucleotide exchange factors. Nature 447: 596-600.
13. Erwig LP, McPhilips KA, Wynes MW, Ivetic A, Ridley AJ, et al. (2006) Differential regulation of phagosome maturation in macrophages and dendritic cells mediated by Rho GTPases and ezrin-radixin-moesin (ERM) proteins. Proc Natl Acad Sci U S A 103: 12825-12830.
14. Cernuda-Morollon E, Ridley AJ (2006) Rho GTPases and leukocyte adhesion receptor expression and function in endothelial cells. Circ Res 98: 757-767.
15. Hahmann C, Schroeter T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell Mol Life Sci 67: 171-177.
16. LoGrasso PV, Feng Y (2009) Rho kinase (ROCK) inhibitors and their application to inflammatory disorders. Curr Top Med Chem 9: 704-723.
17. Aznar S, Lacal JC (2001) Rho signals to cell growth and apoptosis. Cancer Lett 165: 1-10.
18. Tharaux PL, Bukoski RC, Rocha PN, Crowley SD, Ruiz P, et al. (2003) Rho kinase promotes alloimmune responses by regulating the proliferation and structure of T cells. J Immunol 171: 96-105.
19. He Y, Xu H, Liang L, Zhan Z, Yang X, et al. (2008) Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappaB activation in rheumatoid arthritis. Arthritis Rheum 58: 3366-3376.
20. Sun X, Minohara M, Kikuchi H, Ishizu T, Tanaka M, et al. (2006) The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J Neuroimmunol 180: 126-134.
21. Li Y, Wu Y, Wang Z, Zhang XH, Wu WK. Fasudil attenuates lipopolysaccharide-induced acute lung injury in mice through the Rho/Rho kinase pathway. Med Sci Monit 16: BR112-118.
22. Yu JZ, Ding J, Ma CG, Sun CH, Sun YF, et al. Therapeutic potential of experimental autoimmune encephalomyelitis by Fasudil, a Rho kinase inhibitor. J Neurosci Res 88: 1664-1672.
23. Noma K, Oyama N, Liao JK (2006) Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 290: C661-668.
24. Shimokawa H, Seto M, Katsumata N, Amano M, Kozai T, et al. (1999) Rhokinase- mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res 43: 1029-1039.
25. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, et al. (2009) Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 39: 591-602.
26. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, et al. (2003) Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 93: 767-775.
27. Tawara S, Fukumoto Y, Shimokawa H (2007) Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 50: 195-200.
28. Brooks SV, Faulkner JA (1988) Contractile properties of skeletal muscles from young, adult and aged mice. J Physiol 404: 71-82.
29. Tietz NW, ed (1982) Fundamentals of clinical chemistry. Philadelphia: W B Saunders.
30. Spurney CF, Cha HJ, Sali A, Pandey GS, Pistilli E, et al. Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. PLoS One 5: e8976.
31. Suzuki N, Aoki M, Hinuma Y, Takahashi T, Onodera Y, et al. (2005) Expression profiling with progression of dystrophic change in dysferlin-deficient mice (SJL). Neurosci Res 52: 47-60.
32. De Luca A, Nico B, Liantonio A, Didonna MP, Fraysse B, et al. (2005) A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. Am J Pathol 166: 477-489.
33. Alley J, Khasabov S, Simone D, Beitz A, Rodriguez M, et al. (2003) More severe neurologic deficits in SJL/J male than female mice following Theiler's virusinduced CNS demyelination. Exp Neurol 180: 14-24.
34. Knippenberg S, Thau N, Dengler R, Petri S. Significance of behavioural tests in a transgenic mouse model of amyotrophic lateral sclerosis (ALS). Behav Brain Res 213: 82-87.
35. Chiu YH, Hornsey MA, Klinge L, Jorgensen LH, Laval SH, et al. (2009) Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. Hum Mol Genet 18: 1976-1989.
36. Chase TH, Cox GA, Burzenski L, Foreman O, Shultz LD (2009) Dysferlin deficiency and the development of cardiomyopathy in a mouse model of limbgirdle muscular dystrophy 2B. Am J Pathol 175: 2299-2308.
37. Han GM, Zhao B, Jeyaseelan S, Feng JM (2009) Age-associated parallel increase of Foxp3(+)CD4(+) regulatory and CD44(+)CD4(+) memory T cells in SJL/J mice. Cell Immunol 258: 188-196.
38. Nagaraju K, Plotz PH (2002) Animal models of myositis. Rheum Dis Clin North Am 28: 917-933.
39. Scheiffele F, Fuss IJ (2002) Induction of TNBS colitis in mice. Curr Protoc Immunol Chapter 15: Unit 15 19.
40. Gerhauser I, Ulrich R, Alldinger S, Baumgartner W (2007) Induction of activator protein-1 and nuclear factor-kappaB as a prerequisite for disease development in susceptible SJL/J mice after theiler murine encephalomyelitis. J Neuropathol Exp Neurol 66: 809-818.
41. Pollinger B, Krishnamoorthy G, Berer K, Lassmann H, Bosl MR, et al. (2009) Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med 206: 1303-1316.
42. Heiman-Patterson TD, Deitch JS, Blankenhorn EP, Erwin KL, Perreault MJ, et al. (2005) Background and gender effects on survival in the TgN(SOD1- G93A)1Gur mouse model of ALS. J Neurol Sci 236: 1-7.
43. Hidaka T, Suzuki Y, Yamashita M, Shibata T, Tanaka Y, et al. (2008) Amelioration of crescentic glomerulonephritis by RhoA kinase inhibitor, Fasudil, through podocyte protection and prevention of leukocyte migration. Am J Pathol 172: 603-614.
44. Pelosi M, Marampon F, Zani BM, Prudente S, Perlas E, et al. (2007) ROCK2 and its alternatively spliced isoform ROCK2m positively control the maturation of the myogenic program. Mol Cell Biol 27: 6163-6176.
45. Bauer PO, Nukina N (2009) Enhanced degradation of mutant huntingtin by rho kinase inhibition is mediated through activation of proteasome and macroautophagy. Autophagy 5: 747-748.
46. Zhang J, Li XX, Bian HJ, Liu XB, Ji XP, et al. (2009) Inhibition of the activity of Rho-kinase reduces cardiomyocyte apoptosis in heart ischemia/reperfusion via suppressing JNK-mediated AIF translocation. Clin Chim Acta 401: 76-80.
47. Del Re DP, Miyamoto S, Brown JH (2007) RhoA/Rho kinase up-regulate Bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis. J Biol Chem 282: 8069-8078.
48. Shi J, Wei L (2007) Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp (Warsz) 55: 61-75.